365 related articles for article (PubMed ID: 18057928)
21. Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.
Lindfelt T; O'Brien J; Song JC; Patel R; Winslow DL
Ann Pharmacother; 2010 Oct; 44(10):1572-8. PubMed ID: 20841522
[TBL] [Abstract][Full Text] [Related]
22. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
[TBL] [Abstract][Full Text] [Related]
23. Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients.
Sarfo FS; Zhang Y; Egan D; Tetteh LA; Phillips R; Bedu-Addo G; Sarfo MA; Khoo S; Owen A; Chadwick DR
J Antimicrob Chemother; 2014 Feb; 69(2):491-9. PubMed ID: 24080498
[TBL] [Abstract][Full Text] [Related]
24. CYP2B6 G516T polymorphism but not rifampin coadministration influences steady-state pharmacokinetics of efavirenz in human immunodeficiency virus-infected patients in South India.
Ramachandran G; Hemanth Kumar AK; Rajasekaran S; Kumar P; Ramesh K; Anitha S; Narendran G; Menon P; Gomathi C; Swaminathan S
Antimicrob Agents Chemother; 2009 Mar; 53(3):863-8. PubMed ID: 19124658
[TBL] [Abstract][Full Text] [Related]
25. The relationships of ABCB1 3435C>T and CYP2B6 516G>T with high-density lipoprotein cholesterol in HIV-infected patients receiving Efavirenz.
Mahungu TW; Nair D; Smith CJ; Egan D; Youle M; Johnson MA; Khoo SH; Back DJ; Owen A
Clin Pharmacol Ther; 2009 Aug; 86(2):204-11. PubMed ID: 19474786
[TBL] [Abstract][Full Text] [Related]
26. Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26.
Gatanaga H; Hayashida T; Tsuchiya K; Yoshino M; Kuwahara T; Tsukada H; Fujimoto K; Sato I; Ueda M; Horiba M; Hamaguchi M; Yamamoto M; Takata N; Kimura A; Koike T; Gejyo F; Matsushita S; Shirasaka T; Kimura S; Oka S
Clin Infect Dis; 2007 Nov; 45(9):1230-7. PubMed ID: 17918089
[TBL] [Abstract][Full Text] [Related]
27. Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.
Ribaudo HJ; Haas DW; Tierney C; Kim RB; Wilkinson GR; Gulick RM; Clifford DB; Marzolini C; Fletcher CV; Tashima KT; Kuritzkes DR; Acosta EP;
Clin Infect Dis; 2006 Feb; 42(3):401-7. PubMed ID: 16392089
[TBL] [Abstract][Full Text] [Related]
28. CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
Powers V; Ward J; Gompels M
HIV Med; 2009 Sep; 10(8):520-3. PubMed ID: 19486190
[TBL] [Abstract][Full Text] [Related]
29. CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe.
Dhoro M; Zvada S; Ngara B; Nhachi C; Kadzirange G; Chonzi P; Masimirembwa C
BMC Pharmacol Toxicol; 2015 Mar; 16():4. PubMed ID: 25889207
[TBL] [Abstract][Full Text] [Related]
30. Correlation of CYP2B6-516G > T Polymorphism with Plasma Efavirenz Concentration and Depression in HIV-Infected Adults in Northern Thailand.
Aurpibul L; Chotirosniramit N; Sugandhavesa P; Kosashunhanan N; Thetket S; Supindham T; Piyamongkol W; Supparatpinyo K
Curr HIV Res; 2012 Dec; 10(8):653-60. PubMed ID: 22950382
[TBL] [Abstract][Full Text] [Related]
31. CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children.
Saitoh A; Sarles E; Capparelli E; Aweeka F; Kovacs A; Burchett SK; Wiznia A; Nachman S; Fenton T; Spector SA
AIDS; 2007 Oct; 21(16):2191-9. PubMed ID: 18090046
[TBL] [Abstract][Full Text] [Related]
32. Effect of CYP2B6, ABCB1, and CYP3A5 polymorphisms on efavirenz pharmacokinetics and treatment response: an AIDS Clinical Trials Group study.
Ribaudo HJ; Liu H; Schwab M; Schaeffeler E; Eichelbaum M; Motsinger-Reif AA; Ritchie MD; Zanger UM; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford D; Haas DW
J Infect Dis; 2010 Sep; 202(5):717-22. PubMed ID: 20662624
[TBL] [Abstract][Full Text] [Related]
33. Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.
Carr DF; la Porte CJ; Pirmohamed M; Owen A; Cortes CP
J Antimicrob Chemother; 2010 Sep; 65(9):1889-93. PubMed ID: 20639527
[TBL] [Abstract][Full Text] [Related]
34. Importance of ethnicity, CYP2B6 and ABCB1 genotype for efavirenz pharmacokinetics and treatment outcomes: a parallel-group prospective cohort study in two sub-Saharan Africa populations.
Ngaimisi E; Habtewold A; Minzi O; Makonnen E; Mugusi S; Amogne W; Yimer G; Riedel KD; Janabi M; Aderaye G; Mugusi F; Bertilsson L; Aklillu E; Burhenne J
PLoS One; 2013; 8(7):e67946. PubMed ID: 23861838
[TBL] [Abstract][Full Text] [Related]
35. Long-term efavirenz autoinduction and its effect on plasma exposure in HIV patients.
Ngaimisi E; Mugusi S; Minzi OM; Sasi P; Riedel KD; Suda A; Ueda N; Janabi M; Mugusi F; Haefeli WE; Burhenne J; Aklillu E
Clin Pharmacol Ther; 2010 Nov; 88(5):676-84. PubMed ID: 20881953
[TBL] [Abstract][Full Text] [Related]
36. In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype.
Rekić D; Röshammar D; Mukonzo J; Ashton M
Br J Clin Pharmacol; 2011 Apr; 71(4):536-43. PubMed ID: 21395646
[TBL] [Abstract][Full Text] [Related]
37. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
[TBL] [Abstract][Full Text] [Related]
38. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
[TBL] [Abstract][Full Text] [Related]
39. A single-nucleotide polymorphism in CYP2B6 leads to >3-fold increases in efavirenz concentrations in plasma and hair among HIV-infected women.
Gandhi M; Greenblatt RM; Bacchetti P; Jin C; Huang Y; Anastos K; Cohen M; Dehovitz JA; Sharp GB; Gange SJ; Liu C; Hanson SC; Aouizerat B;
J Infect Dis; 2012 Nov; 206(9):1453-61. PubMed ID: 22927450
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
